|
Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). |
|
|
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BluePrint Medicines; Bristol-Myers Squibb; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Synthon; Taiho Pharmaceutical |
Research Funding - ADC Therapeutics (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Other Relationship - Roche |
|
Rafael Villanueva-Vásquez |
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Lilly; Novartis |
Travel, Accommodations, Expenses - Eisai; Lilly; Novartis; Pfizer |
Other Relationship - Roche |
|
|
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals |
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst) |
|
|
|
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Merck; Novartis; Pfizer; Puma Biotechnology; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Merck; Novartis; Pfizer; Puma Biotechnology; Roche |
Research Funding - Astellas Pharma; AstraZeneca; Genentech; Novartis; OncoGenex; Roche |
Other Relationship - Roche |
|
|
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 |
Travel, Accommodations, Expenses - Lilly |
|
|
Honoraria - Radius Health |
Consulting or Advisory Role - Guidepoint Pharmacy |
Other Relationship - Roche |
|
Jose Alejandro Perez-Fidalgo |
Consulting or Advisory Role - Ability Pharma; Amgen; AstraZeneca; Clovis Oncology; Roche; Tesaro |
Speakers' Bureau - AstraZeneca Spain; GlaxoSmithKline; Ipsen; Novartis; Pfizer; PharmaMar; Roche |
Patents, Royalties, Other Intellectual Property - Pending patent |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst) |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Other Relationship - Roche Medical writing support |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Other Relationship - Roche |
|
|
Employment - PRO Unlimited |
Other Relationship - Roche |
|
|
|
Stock and Other Ownership Interests - Genentech |
Other Relationship - Roche |
|
|
|
Stock and Other Ownership Interests - Roche/Genentech |
Other Relationship - Roche |
|
|
|
Stock and Other Ownership Interests - Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
|
Stock and Other Ownership Interests - Roche |
Other Relationship - Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Zeno Pharmaceuticals |
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Pfizer (Inst); Roche (Inst) |
Other Relationship - Roche |
|
|
Honoraria - AstraZeneca; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Eisai; Novartis; Roche |
Expert Testimony - AstraZeneca; Eisai; Novartis; Roche |
Travel, Accommodations, Expenses - Novartis; Roche |
Other Relationship - Roche |
|
|
Research Funding - Roche (Inst) |
Other Relationship - Roche |
|
|
Honoraria - Lilly; Novartis; Pfizer |
Consulting or Advisory Role - Lilly; Novartis |
Speakers' Bureau - Lilly; Novartis; Pfizer |
Travel, Accommodations, Expenses - Pfizer |
Other Relationship - Roche |